Evidence map›Paper›PMID 41463202›Full record

ReviewCancers2025

Surgical Management of Locally Advanced and Metastatic Gallbladder Cancer.

Mitchell Breitenbach, Paul Burchard, Veer Kothari, Darren Carpizo

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mitchell BreitenbachDepartment of Surgery, Division of General Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA.ORCID 0009-0000-6676-7835
Paul BurchardDepartment of Surgery, Division of General Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA.ORCID 0000-0001-7370-5608
Veer KothariDepartment of Surgery, Division of Surgical Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA.
Darren CarpizoDepartment of Surgery, Division of Surgical Oncology, University of Rochester Medical Center, Rochester, NY 14642, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in systemic therapy for gastrointestinal malignancies have opened the door for surgical resection of tumors previously deemed unresectable. Of these tumors, gallbladder cancer has a particularly poor prognosis due to the aggressive nature of the disease. The preferred systemic therapy regimen for gallbladder cancer has progressed from single-agent chemotherapy to multi-agent therapy including immune checkpoint inhibitors, with additional targeted therapies currently under investigation. These advancements have provided patients with historically unresectable tumors with a bridge to surgical resection and a hope of extended survival or cure. Surgical options for locally advanced tumors have expanded, and experienced centers perform a variety of operations to achieve resection with negative margins, including extended liver resection, bile duct resection, vascular reconstruction, and adjacent organ resection. There is also growing evidence that patients with Stage IV disease may benefit from resection of their primary tumors and metastases. This review outlines the current treatment practices for patients with locally invasive and metastatic gallbladder cancer as well as emerging treatment options.

Indexed as

bile duct resectiongallbladder cancerhepatic resectionlocally advanced diseasemetastasectomymetastatic diseaseportal vein embolizationradical cholecystectomysurgical resectionsystemic therapy

Identifiers

PMID41463202
PMCPMC12730383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.